SCHEMBL1787822

SCHEMBL1787822

O=C(ONC1CCCCC1)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 10/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
RAB9A P51151 4/20 0.40
EPHX2 P34913 3/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27746258 1.00 EPHX1 (0.41) EPHX1PDK1PDK2PDK3PDK4
SCHEMBL28626663 0.94 EPHX1 (0.34) EPHX1PDK1PDK2PDK3PDK4
SCHEMBL27716512 0.90 PKM (0.36)
SCHEMBL10950148 0.80 EPHX1 (0.41) EPHX1RAB9AEPHX2NPC1SMN1; SMN2
SCHEMBL27805832 0.80 GAA (0.42) EPHX1PDK1PDK2PDK3PDK4
SCHEMBL14738908 0.79 CCR2 (0.32) EPHX1EPHX2
Ammonia Solution, Strong SCHEMBL28219804 0.78 GAA (0.41) EPHX1PDK1PDK2PDK3PDK4
SCHEMBL4114063 0.78 PDK1 (0.36) EPHX1PDK1PDK2PDK3PDK4
Water SCHEMBL28072177 0.78 GAA (0.41) EPHX1PDK1PDK2PDK3PDK4
SCHEMBL7291838 0.77 EPHX2 (0.32) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633175-B2 Compounds as antagonists or inverse agonists at opioid receptors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
CN-103492370-A Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith SIGNAL PHARM LLC 2014-01-01 CN disclosed
CN-102753522-B Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2013-11-27 CN disclosed
CN-102753522-A Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2012-10-24 CN disclosed
CN-102159207-A Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2011-08-17 CN disclosed
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2011-05-26 US disclosed
CN-100343304-C Hydrolytically stable maleimide-terminated polymers NEKTAR THERAPEUTICS AL CORP (US) 2007-10-17 CN disclosed
CN-1732206-A Hydrolytically stable maleimide-terminated polymers NEKTAR THERAPEUTICS AL CORP (US) 2006-02-08 CN disclosed
US-4048228-A Substituted cyanamidic compounds UOP INC. (US) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 EPHX1 1978/4885PDK1 4364/4885PDK2 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.